N/A N=2,221 Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa
Kangaroo Mother Care · Preterm Infant · Death; Neonatal
Primary: Mortality Within 7 Days — 81; 83 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=100 Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.
Acute Respiratory Viral Infections · Human Influenza
Primary: Efficacy: Number of Participants -- Absence of Objective Symptoms -- Overall — 0; 0; 0; 0 Participants — p=0.5547
Phase 1 N=56 First in Human Study of a Monoclonal Antibody (SOL-116) Targeting BSSL (Bile Salt-Stimulated Lipase), Single and Multiple Dose Parts
Rheumatoid Arthritis
Primary: Safety and Tolerability: Adverse Events — 7; 9; 8; 8 number of events
N/A N=179 Mobile Self-Management Program for Stress Reduction in Young Adults
Stress (Psychology)
Primary: Stress at Week 8 — 19.41; 18.35 score on a scale
Phase 2 N=24 A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
Obesity
Primary: Part 1: Number of Treatment-emergent Adverse Events (TEAEs) — 56; 71; 37 Events
N/A N=94 Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection
Melanoma
Primary: Number of Participants Interviewed on UVR Protection Behaviors. — 25; 0; 0; 59 Participants
Phase 4 N=53 Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
Alzheimer Disease
Primary: Change From Baseline Measure in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) at 8, 16 and 24 Weeks — 19.76; 19.81; 19.94; 20.79 scores on a scale…
Phase 2 N=17 Hydroxyurea and EPO in Sickle Cell Disease
Anemia, Sickle Cell · Sickle Cell Disease
Primary: Percentage of Participants With Hemoglobin (Hb) Response — 15 Participants
Phase 2 N=45 Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA
Osteoarthritis (OA)
Primary: Change From Baseline in Cartilage Volume in the Index Region Measured by 7 Tesla MRI — 63.3; 49.8; 11.6 µL — p=0.2366
Phase 2 N=352 Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)
HIV · HIV Pre-exposure Prophylaxis
Primary: Number of Participants With ≥1 Adverse Event (AE) — 62; 69; 66; 31 Participants
N/A N=34 PROMISE International
Critical Limb Ischemia
Primary: Amputation-free Survival — 50.7 percentage of participants
N/A N=28 Clinical Investigation on the Use of Ophthalmic Solution Based on Sodium Hyaluronate in Treatment of Eye Discomfort
Ocular Dryness
Primary: Tear Film Break-up Time With Fluorescein (TFBUT) — 5.00; 13.46 Second
N/A N=107 Effectiveness and Cost-effectiveness of iCBT-I in Clinical Settings
Chronic Insomnia
Primary: Insomnia Severity Index (ISI) — 10.0; 13.5; 11.3; 13.1 units on a scale
N/A N=89 Functional Interval Training for Veterans Exercising Through Telehealth.
HIV Infection
Primary: Change From Baseline VO2peak to After 12-week Exercise Intervention — 1.99; 2.05; 2.07; 2.07 Liters/minute
Phase 3 N=71 Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)
Pediatric Acute-Onset Neuropsychiatric Syndrome
Primary: Percentage Change in CY-BOCS Score From Baseline to Week 9 — 12.1; 31.1 Percentage Change at Week 9 to Baseline — p=0.0718